Department of Introduction to Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow, Russian Federation.
Scientific Department, The Interregional Public Organization "Scientific Community for the Promotion of the Clinical Study of the Human Microbiome", Moscow, Russian Federation.
Infect Dis (Lond). 2021 May;53(5):348-360. doi: 10.1080/23744235.2021.1885733. Epub 2021 Feb 15.
Diarrhoea is a relatively common manifestation of coronavirus disease (COVID-19), but there is no systematic review which comprehensively describes it beyond its incidence and impact on prognosis. This study aims to provide a detailed systematic review of diarrhoea in adults with COVID-19.
A PUBMED and Scopus search (until 7 September 2020) was performed. Studies that were limited to describing incidence of diarrhoea and its effect on prognosis were excluded.
Twenty-six papers including 7860 patients with COVID-19 were subjected to synthesis. Mean duration of diarrhoea was 4.2 (3.6-4.9) days (range 1-16 days), whereas mean bowel movement count was 4.6 (3.8-5.3) and maximum was 20 per day. Diarrhoea started on an average 5.1 (3.8-6.5) days after disease onset but was the first manifestation in 4.3% patients. Stool occult blood was detected in 6.8% of patients with diarrhoea, while 53.3% cases had watery diarrhoea. Patients with diarrhoea also had elevated faecal calprotectin. Viral genome in faeces was detected more often in patients with diarrhoea and most often in patients without respiratory symptoms. Fever, myalgia and respiratory symptoms were observed with the same incidence in patients with and without diarrhoea. Similarly, there were no differences noted in complete blood count and most inflammation biomarkers between patients with and without diarrhoea. However, nausea, vomiting abdominal pain, sneezing and headache were more common in patients with diarrhoea. Diarrhoea was the main manifestation of COVID-19 in 6.1% of cases and this form of the disease had specific features.
Diarrhoea in COVID-19 needs further investigation.
腹泻是冠状病毒病（COVID-19）的一种相对常见的表现，但除了发病率及其对预后的影响外，尚无系统评价对其进行全面描述。本研究旨在对 COVID-19 成人患者腹泻进行详细的系统评价。
在 PUBMED 和 Scopus 上进行检索（截至 2020 年 9 月 7 日）。排除仅描述腹泻发病率及其对预后影响的研究。
26 篇文献包括 7860 例 COVID-19 患者进行了综合分析。腹泻的平均持续时间为 4.2（3.6-4.9）天（范围 1-16 天），平均排便次数为 4.6（3.8-5.3）次，最多为 20 次/天。腹泻平均在发病后 5.1（3.8-6.5）天开始，但在 4.3%的患者中为首发症状。腹泻患者粪便潜血检测阳性率为 6.8%，53.3%为水样便。腹泻患者粪便钙卫蛋白升高。腹泻患者粪便中更常检测到病毒基因组，且最常发生于无呼吸道症状的患者。发热、肌痛和呼吸道症状在腹泻患者和无腹泻患者中发生率相同。同样，腹泻患者和无腹泻患者之间的全血细胞计数和大多数炎症生物标志物无差异。然而，腹泻患者更常出现恶心、呕吐、腹痛、打喷嚏和头痛。腹泻是 COVID-19 的主要表现，占 6.1%，这种疾病有其特定特征。
COVID-19 腹泻需要进一步研究。
